Cargando…
Live attenuated Salmonella typhimurium vaccines delivering SaEsxA and SaEsxB via type III secretion system confer protection against Staphylococcus aureus infection
BACKGROUND: Staphylococcus aureus (S. aureus) causes a wide range of infectious diseases in human and animals. The emergence of antibiotic-resistant strains demands novel strategies for prophylactic vaccine development. In this study, live attenuated S. enterica subsp. enterica serotype Typhimurium...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5921394/ https://www.ncbi.nlm.nih.gov/pubmed/29699491 http://dx.doi.org/10.1186/s12879-018-3104-y |
_version_ | 1783318001081122816 |
---|---|
author | Xu, Chen Zhang, Bao-zhong Lin, Qiubin Deng, Jian Yu, Bin Arya, Smriti Yuen, Kwok-Yung Huang, Jian-Dong |
author_facet | Xu, Chen Zhang, Bao-zhong Lin, Qiubin Deng, Jian Yu, Bin Arya, Smriti Yuen, Kwok-Yung Huang, Jian-Dong |
author_sort | Xu, Chen |
collection | PubMed |
description | BACKGROUND: Staphylococcus aureus (S. aureus) causes a wide range of infectious diseases in human and animals. The emergence of antibiotic-resistant strains demands novel strategies for prophylactic vaccine development. In this study, live attenuated S. enterica subsp. enterica serotype Typhimurium (S. Typhimurium) vaccine against S. aureus infection was developed, in which Salmonella Pathogenesis Island-1 Type 3 Secretion System (SPI-1 T3SS) was employed to deliver SaEsxA and SaEsxB, two of ESAT-6-like (Early Secreted Antigenic Target-6) virulence factors of S. aureus. METHODS: Antigens SaEsxA and SaEsxB were fused with the N-terminal secretion and translocation domain of SPI-1 effector SipA. And cytosolic delivery of Staphylococcal antigens into macrophages was examined by western blot. BALB/c mice were orally immunized with S. Typhimurium-SaEsxA and S. Typhimurium-SaEsxB vaccines. Antigen-specific humoral and Th1/Th17 immune responses were examined by ELISA and ELISPOT assays 7–9 days after the 2nd booster. For ELISPOT assays, the statistical significance was determined by Student’s t test. The vaccine efficacy was evaluated by lethal challenge with two S. aureus clinical isolates Newman strain and USA 300 strain. Statistical significance was determined by Log rank (Mantel-Cox) analysis. And a P value of < 0.05 was considered statistically significant. RESULTS: Oral administration of S. Typhimurium-SaEsxA and S. Typhimurium-SaEsxB vaccines induced antigen-specific humoral and Th1/Th17 immune responses, which increased the survival rate for vaccinated mice when challenged with S. aureus strains. CONCLUSIONS: The newly developed S. Typhimurium-based vaccines delivering SaEsxA and SaEsxB by SPI-1 T3SS could confer protection against S. aureus infection. This study provides evidence that translocation of foreign antigens via Salmonella SPI-1 T3SS into the cytosol of antigen presenting cells (APCs) could induce potent immune responses against pathogens. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12879-018-3104-y) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5921394 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-59213942018-05-01 Live attenuated Salmonella typhimurium vaccines delivering SaEsxA and SaEsxB via type III secretion system confer protection against Staphylococcus aureus infection Xu, Chen Zhang, Bao-zhong Lin, Qiubin Deng, Jian Yu, Bin Arya, Smriti Yuen, Kwok-Yung Huang, Jian-Dong BMC Infect Dis Research Article BACKGROUND: Staphylococcus aureus (S. aureus) causes a wide range of infectious diseases in human and animals. The emergence of antibiotic-resistant strains demands novel strategies for prophylactic vaccine development. In this study, live attenuated S. enterica subsp. enterica serotype Typhimurium (S. Typhimurium) vaccine against S. aureus infection was developed, in which Salmonella Pathogenesis Island-1 Type 3 Secretion System (SPI-1 T3SS) was employed to deliver SaEsxA and SaEsxB, two of ESAT-6-like (Early Secreted Antigenic Target-6) virulence factors of S. aureus. METHODS: Antigens SaEsxA and SaEsxB were fused with the N-terminal secretion and translocation domain of SPI-1 effector SipA. And cytosolic delivery of Staphylococcal antigens into macrophages was examined by western blot. BALB/c mice were orally immunized with S. Typhimurium-SaEsxA and S. Typhimurium-SaEsxB vaccines. Antigen-specific humoral and Th1/Th17 immune responses were examined by ELISA and ELISPOT assays 7–9 days after the 2nd booster. For ELISPOT assays, the statistical significance was determined by Student’s t test. The vaccine efficacy was evaluated by lethal challenge with two S. aureus clinical isolates Newman strain and USA 300 strain. Statistical significance was determined by Log rank (Mantel-Cox) analysis. And a P value of < 0.05 was considered statistically significant. RESULTS: Oral administration of S. Typhimurium-SaEsxA and S. Typhimurium-SaEsxB vaccines induced antigen-specific humoral and Th1/Th17 immune responses, which increased the survival rate for vaccinated mice when challenged with S. aureus strains. CONCLUSIONS: The newly developed S. Typhimurium-based vaccines delivering SaEsxA and SaEsxB by SPI-1 T3SS could confer protection against S. aureus infection. This study provides evidence that translocation of foreign antigens via Salmonella SPI-1 T3SS into the cytosol of antigen presenting cells (APCs) could induce potent immune responses against pathogens. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12879-018-3104-y) contains supplementary material, which is available to authorized users. BioMed Central 2018-04-25 /pmc/articles/PMC5921394/ /pubmed/29699491 http://dx.doi.org/10.1186/s12879-018-3104-y Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Xu, Chen Zhang, Bao-zhong Lin, Qiubin Deng, Jian Yu, Bin Arya, Smriti Yuen, Kwok-Yung Huang, Jian-Dong Live attenuated Salmonella typhimurium vaccines delivering SaEsxA and SaEsxB via type III secretion system confer protection against Staphylococcus aureus infection |
title | Live attenuated Salmonella typhimurium vaccines delivering SaEsxA and SaEsxB via type III secretion system confer protection against Staphylococcus aureus infection |
title_full | Live attenuated Salmonella typhimurium vaccines delivering SaEsxA and SaEsxB via type III secretion system confer protection against Staphylococcus aureus infection |
title_fullStr | Live attenuated Salmonella typhimurium vaccines delivering SaEsxA and SaEsxB via type III secretion system confer protection against Staphylococcus aureus infection |
title_full_unstemmed | Live attenuated Salmonella typhimurium vaccines delivering SaEsxA and SaEsxB via type III secretion system confer protection against Staphylococcus aureus infection |
title_short | Live attenuated Salmonella typhimurium vaccines delivering SaEsxA and SaEsxB via type III secretion system confer protection against Staphylococcus aureus infection |
title_sort | live attenuated salmonella typhimurium vaccines delivering saesxa and saesxb via type iii secretion system confer protection against staphylococcus aureus infection |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5921394/ https://www.ncbi.nlm.nih.gov/pubmed/29699491 http://dx.doi.org/10.1186/s12879-018-3104-y |
work_keys_str_mv | AT xuchen liveattenuatedsalmonellatyphimuriumvaccinesdeliveringsaesxaandsaesxbviatypeiiisecretionsystemconferprotectionagainststaphylococcusaureusinfection AT zhangbaozhong liveattenuatedsalmonellatyphimuriumvaccinesdeliveringsaesxaandsaesxbviatypeiiisecretionsystemconferprotectionagainststaphylococcusaureusinfection AT linqiubin liveattenuatedsalmonellatyphimuriumvaccinesdeliveringsaesxaandsaesxbviatypeiiisecretionsystemconferprotectionagainststaphylococcusaureusinfection AT dengjian liveattenuatedsalmonellatyphimuriumvaccinesdeliveringsaesxaandsaesxbviatypeiiisecretionsystemconferprotectionagainststaphylococcusaureusinfection AT yubin liveattenuatedsalmonellatyphimuriumvaccinesdeliveringsaesxaandsaesxbviatypeiiisecretionsystemconferprotectionagainststaphylococcusaureusinfection AT aryasmriti liveattenuatedsalmonellatyphimuriumvaccinesdeliveringsaesxaandsaesxbviatypeiiisecretionsystemconferprotectionagainststaphylococcusaureusinfection AT yuenkwokyung liveattenuatedsalmonellatyphimuriumvaccinesdeliveringsaesxaandsaesxbviatypeiiisecretionsystemconferprotectionagainststaphylococcusaureusinfection AT huangjiandong liveattenuatedsalmonellatyphimuriumvaccinesdeliveringsaesxaandsaesxbviatypeiiisecretionsystemconferprotectionagainststaphylococcusaureusinfection |